FDA-AACR Workshop to Address Multiple Myeloma Clinical Trial Disparities
By Trevan Locke, PhD Thanks to a wave of newly approved therapies in the past two decades, survival rates...
Tag: Multiple myeloma
By Trevan Locke, PhD Thanks to a wave of newly approved therapies in the past two decades, survival rates...
Multiple myeloma arises in immune cells called plasma cells. It is one of the most commonly diagnosed hematological malignancies...
Myeloma is the third most common blood cancer in the United States, arising in the plasma cells of the...
On Monday, the U.S. Food and Drug Administration (FDA) rounded out an exciting month for the multiple myeloma community...
The flurry of decisions from the U.S. Food and Drug Administration (FDA) on investigational anticancer therapeutics continued last week...
Just days before the start of multiple myeloma awareness month, which began Sunday, March 1, the U.S. Food and...